Bai Yuwei, Wang Xiaoyun, Wang Bei
Institute of Integration of Traditional Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, People's Republic of China.
Wuxi School of Medicine, Jiangnan University, Wuxi, People's Republic of China.
Immunotargets Ther. 2025 Jan 23;14:35-49. doi: 10.2147/ITT.S486609. eCollection 2025.
Cancer is a widespread epidemic that affects millions of individuals across the world. Identifying novel cancer targets is crucial to developing more effective cancer treatments. Platelet-derived growth factor-B (PDGFB) plays a critical role in various tumor processes, including angiogenesis and lymphatic metastasis. However, there is a lack of research on the role of PDGFB in these processes.
To address this issue, we conducted a comprehensive analysis utilizing multiple online databases to investigate the expression, prognostic, tumor stemness, and immunological effect of PDGFB. In addition, clinical samples were validated using immunohistochemistry.
Our findings revealed that PDGFB was highly expressed in a diverse range of cancer types, and its expression and genetic modifications were significantly associated with clinical outcomes in certain tumors. In general, high expression of PDGFB in tumors is associated with poor prognosis. Surprisingly, PDGFB was found to be highly expressed in renal clear cell carcinoma but was associated with good prognosis. In contrast, PDGFB was low expressed in lung carcinoma, but its expression was found to improve patient survival. These findings demonstrate the complex role of PDGFB in different cancer types. The study also demonstrated that PDGFB was linked to RNA and DNA stemness in 15 and 36 tumor types, respectively, and had a positive association with tumor lymphocyte infiltration. Notably, PDGFB was found to be associated with immune modulators. PDGFB, which is involved in various immune responses, influences the malignant characteristics of various cancer types and controls immune cell infiltration. We confirmed that PDGFB positively correlated with CD8 and PDL1 expression in lower grade glioma.
This study concludes that PDGFB may serve as a potential prognostic marker and a potential targetable pathway in cancer immunotherapy. Overall, the study sheds new light on the role of PDGFB in cancer and highlights its potential clinical significance.
癌症是一种广泛流行的疾病，影响着全球数百万人。确定新的癌症靶点对于开发更有效的癌症治疗方法至关重要。血小板衍生生长因子-B（PDGFB）在包括血管生成和淋巴转移在内的各种肿瘤过程中起着关键作用。然而，关于PDGFB在这些过程中的作用缺乏研究。
为了解决这个问题，我们利用多个在线数据库进行了全面分析，以研究PDGFB的表达、预后、肿瘤干性和免疫效应。此外，使用免疫组织化学对临床样本进行了验证。
我们的研究结果表明，PDGFB在多种癌症类型中高表达，其表达和基因修饰在某些肿瘤中与临床结果显著相关。一般来说，肿瘤中PDGFB的高表达与预后不良有关。令人惊讶的是，发现PDGFB在肾透明细胞癌中高表达，但与良好的预后相关。相反，PDGFB在肺癌中低表达，但其表达被发现可改善患者生存。这些发现证明了PDGFB在不同癌症类型中的复杂作用。该研究还表明，PDGFB分别与15种和36种肿瘤类型的RNA和DNA干性相关，并与肿瘤淋巴细胞浸润呈正相关。值得注意的是，发现PDGFB与免疫调节剂有关。参与各种免疫反应的PDGFB影响各种癌症类型的恶性特征并控制免疫细胞浸润。我们证实，在低级别胶质瘤中，PDGFB与CD8和PDL1表达呈正相关。
本研究得出结论，PDGFB可能作为一种潜在的预后标志物和癌症免疫治疗中的潜在可靶向途径。总体而言，该研究为PDGFB在癌症中的作用提供了新的见解，并突出了其潜在的临床意义。
